![](/img/cover-not-exists.png)
Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)
P. Rougier, D. Cunningham, A.D. Roth, J.R. Germa, R.D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, G. Gruia, M. Alakl, D. Sibaud, J.Y. DouillardVolume:
35
Year:
1999
Language:
english
DOI:
10.1016/s0959-8049(99)80639-x
File:
PDF, 117 KB
english, 1999